vs

Side-by-side financial comparison of VAALCO ENERGY INC (EGY) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

VAALCO ENERGY INC is the larger business by last-quarter revenue ($91.0M vs $74.7M, roughly 1.2× Health Catalyst, Inc.). VAALCO ENERGY INC runs the higher net margin — -64.4% vs -121.9%, a 57.5% gap on every dollar of revenue. On growth, Health Catalyst, Inc. posted the faster year-over-year revenue change (-6.2% vs -25.2%). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -4.7%).

VAALCO Energy is a company engaged in hydrocarbon exploration. It is organized in Delaware and headquartered in Houston, Texas with operations primarily in the Etame Marin block offshore Gabon.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

EGY vs HCAT — Head-to-Head

Bigger by revenue
EGY
EGY
1.2× larger
EGY
$91.0M
$74.7M
HCAT
Growing faster (revenue YoY)
HCAT
HCAT
+19.0% gap
HCAT
-6.2%
-25.2%
EGY
Higher net margin
EGY
EGY
57.5% more per $
EGY
-64.4%
-121.9%
HCAT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-4.7%
EGY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EGY
EGY
HCAT
HCAT
Revenue
$91.0M
$74.7M
Net Profit
$-58.6M
$-91.0M
Gross Margin
Operating Margin
-71.3%
-115.3%
Net Margin
-64.4%
-121.9%
Revenue YoY
-25.2%
-6.2%
Net Profit YoY
-602.5%
-340.3%
EPS (diluted)
$-0.56
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EGY
EGY
HCAT
HCAT
Q4 25
$91.0M
$74.7M
Q3 25
$61.0M
$76.3M
Q2 25
$96.9M
$80.7M
Q1 25
$110.3M
$79.4M
Q4 24
$121.7M
$79.6M
Q3 24
$140.3M
$76.4M
Q2 24
$116.8M
$75.9M
Q1 24
$100.2M
$74.7M
Net Profit
EGY
EGY
HCAT
HCAT
Q4 25
$-58.6M
$-91.0M
Q3 25
$1.1M
$-22.2M
Q2 25
$8.4M
$-41.0M
Q1 25
$7.7M
$-23.7M
Q4 24
$11.7M
$-20.7M
Q3 24
$11.0M
$-14.7M
Q2 24
$28.2M
$-13.5M
Q1 24
$7.7M
$-20.6M
Gross Margin
EGY
EGY
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
EGY
EGY
HCAT
HCAT
Q4 25
-71.3%
-115.3%
Q3 25
1.5%
-22.9%
Q2 25
17.7%
-46.0%
Q1 25
23.7%
-25.4%
Q4 24
32.7%
-22.0%
Q3 24
31.4%
-17.9%
Q2 24
17.5%
-20.8%
Q1 24
32.1%
-30.5%
Net Margin
EGY
EGY
HCAT
HCAT
Q4 25
-64.4%
-121.9%
Q3 25
1.8%
-29.1%
Q2 25
8.6%
-50.8%
Q1 25
7.0%
-29.9%
Q4 24
9.6%
-26.0%
Q3 24
7.8%
-19.3%
Q2 24
24.1%
-17.8%
Q1 24
7.7%
-27.6%
EPS (diluted)
EGY
EGY
HCAT
HCAT
Q4 25
$-0.56
$-1.29
Q3 25
$0.01
$-0.32
Q2 25
$0.08
$-0.59
Q1 25
$0.07
$-0.35
Q4 24
$0.12
$-0.33
Q3 24
$0.10
$-0.24
Q2 24
$0.27
$-0.23
Q1 24
$0.07
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EGY
EGY
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$58.9M
$95.7M
Total DebtLower is stronger
$60.0M
$153.3M
Stockholders' EquityBook value
$443.5M
$245.8M
Total Assets
$913.4M
$502.6M
Debt / EquityLower = less leverage
0.14×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EGY
EGY
HCAT
HCAT
Q4 25
$58.9M
$95.7M
Q3 25
$24.0M
$91.5M
Q2 25
$67.9M
$97.3M
Q1 25
$40.9M
$342.0M
Q4 24
$82.7M
$392.0M
Q3 24
$89.1M
$387.3M
Q2 24
$62.9M
$308.3M
Q1 24
$113.3M
$327.8M
Total Debt
EGY
EGY
HCAT
HCAT
Q4 25
$60.0M
$153.3M
Q3 25
$60.0M
$153.1M
Q2 25
$60.0M
$153.0M
Q1 25
$0
$382.9M
Q4 24
$0
$382.4M
Q3 24
$0
$345.0M
Q2 24
$0
Q1 24
$0
Stockholders' Equity
EGY
EGY
HCAT
HCAT
Q4 25
$443.5M
$245.8M
Q3 25
$505.9M
$331.9M
Q2 25
$511.6M
$347.5M
Q1 25
$504.1M
$376.8M
Q4 24
$501.6M
$365.2M
Q3 24
$501.0M
$355.0M
Q2 24
$493.6M
$357.0M
Q1 24
$472.6M
$357.2M
Total Assets
EGY
EGY
HCAT
HCAT
Q4 25
$913.4M
$502.6M
Q3 25
$950.4M
$587.1M
Q2 25
$964.9M
$616.2M
Q1 25
$927.1M
$891.5M
Q4 24
$955.0M
$858.9M
Q3 24
$937.9M
$813.0M
Q2 24
$917.4M
$691.7M
Q1 24
$809.1M
$695.1M
Debt / Equity
EGY
EGY
HCAT
HCAT
Q4 25
0.14×
0.62×
Q3 25
0.12×
0.46×
Q2 25
0.12×
0.44×
Q1 25
0.00×
1.02×
Q4 24
0.00×
1.05×
Q3 24
0.00×
0.97×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EGY
EGY
HCAT
HCAT
Operating Cash FlowLast quarter
$145.2M
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EGY
EGY
HCAT
HCAT
Q4 25
$145.2M
$9.9M
Q3 25
$16.4M
$-464.0K
Q2 25
$18.3M
$-9.0M
Q1 25
$32.7M
$280.0K
Q4 24
$44.5M
$-3.5M
Q3 24
$47.8M
$6.2M
Q2 24
$-438.0K
$1.6M
Q1 24
$21.8M
$10.3M
Free Cash Flow
EGY
EGY
HCAT
HCAT
Q4 25
$9.6M
Q3 25
$-719.0K
Q2 25
$-9.2M
Q1 25
$29.7M
$-390.0K
Q4 24
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
Q1 24
$10.1M
FCF Margin
EGY
EGY
HCAT
HCAT
Q4 25
12.9%
Q3 25
-0.9%
Q2 25
-11.4%
Q1 25
26.9%
-0.5%
Q4 24
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Q1 24
13.5%
Capex Intensity
EGY
EGY
HCAT
HCAT
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
2.7%
0.8%
Q4 24
0.5%
Q3 24
0.9%
Q2 24
0.4%
Q1 24
0.3%
Cash Conversion
EGY
EGY
HCAT
HCAT
Q4 25
Q3 25
14.94×
Q2 25
2.19×
Q1 25
4.23×
Q4 24
3.82×
Q3 24
4.35×
Q2 24
-0.02×
Q1 24
2.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EGY
EGY

Crude Oil Sales And Purchase Agreements$54.8M60%
Other$31.9M35%
Crude Oil$3.0M3%
Natural Gas Liquids Reserves$1.4M2%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons